Agilent Technologies (California, USA) is to collaborate with Seoul National University (Seoul, South Korea) to open a new research centre that will support the College of Pharmacy?s New Drug Development Centre.
Agilent Technologies (California, USA) is to collaborate with Seoul National University (Seoul, South Korea) to open a new research centre that will support the College of Pharmacy’s New Drug Development Centre.
The new centre aims to conduct drug metabolism studies; research, evaluate, and develop new compounds; understand the remedial effects and toxicity; assess pharmokinetics; and conduct clinical tests for drugs. Agilent will provide bioanalytical instruments and multi-omic systems to the college. The new centre will also be Agilent’s reference site for drug development.
Professor Bong-Jin Lee, dean of the college, said: “The College of Pharmacy at Seoul National University has a long tradition of driving innovation.” He added: "We have been leading Korea's pharmaceutical industry through the strategic use of technology and driving the development of new drugs. As we prepare students for the future, we will push the frontiers of drug development by expanding our research facilities, producing outstanding research, and leading the development of technology. We are pleased to collaborate with Agilent, as our scientists and researchers require the latest, most sophisticated instruments for their work."
Rod Minett, general manager, Life Sciences, South Korea and South Asia-Pacific region, said: "One of the megatrends fuelling life science research is the ageing population." He added: “Through continual research, trials, and developments, we believe that newer, more effective drugs can be developed. As such, Agilent is pleased to support SNU College of Pharmacy's drive to create better drugs for a safer and healthier population."
For more information visit: ref="http://www.agilent.com">www.agilent.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Frontage Laboratories Streamlines their Product Lifecycle Management with NuGenesis™ LMS
January 9th 2025Frontage laboratories wanted to improve the efficiency and quality of their operations and invest in ways to streamline their workflows. They implemented Waters NuGenesis™ Lab Management System (LMS) to progress their digital transformation journey and combine synergistic data, workflow, and sample management capabilities to support the entire product lifecycle from discovery through manufacturing.
The Intricacies of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.